Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

0.7547 -0.0191 (-2.47%)
Streaming Delayed Price Updated: 3:21 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,019
Open 0.7656
Bid (Size) 0.7532 (500)
Ask (Size) 0.7689 (200)
Prev. Close 0.7738
Today's Range 0.7278 - 0.7798
52wk Range 0.6000 - 2.450
Shares Outstanding 41,876,087
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? ↗
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief. 
Via Benzinga
News headline image
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission 
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-49.3%
-49.3%
1 Month
-3.3%
-3.3%
3 Month
-19.0%
-19.0%
6 Month
-37.6%
-37.6%
1 Year
-45.3%
-45.3%

More News

Read More
News headline image
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
From Mira Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
From MIRA Pharmaceuticals
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Via ACCESS Newswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
What's Going On With MIRA Pharma Stock Tuesday? ↗
Via Benzinga
News headline image
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Via ACCESS Newswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 0.7547
When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 09/14/26 03:21 PM ET
What is the market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock?
The market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock is 31.60M
How many shares of MIRA Pharmaceuticals, Inc. - Common Stock are outstanding?
MIRA Pharmaceuticals, Inc. - Common Stock has 32M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.